Clindamycin hydrochloride and clavulanate-amoxycillin in the treatment of canine superficial pyoderma.
A masked, randomised, controlled clinical trial for the treatment of canine superficial pyoderma was undertaken. Dogs with a clinical diagnosis of superficial pyoderma, supported by bacterial culture were admitted to the trial and randomly assigned to treatment with either clindamycin hydrochloride at 5.5 mg/kg twice daily or clavulanate-amoxycillin at 12.5 mg/kg twice daily. After 21 days the animals were re-assessed, and therapy was continued for a further 21 days in the dogs with persistent lesions if bacterial culture demonstrated continued sensitivity. Twenty-nine dogs were treated with clindamycin hydrochloride and 27 with clavulanate-amoxycillin. Complete cure was obtained after three weeks in 17 (59 per cent) of the clindamycin-treated cases, but in only eight (30 per cent) of the clavulanate-amoxycillin treated group. Clindamycin was significantly more effective than clavulanate-amoxycillin for the treatment of superficial pyoderma in dogs.
Littlewood
J D
JD
Centre for Small Animal Studies, Animal Health Trust, Newmarket, Suffolk.
Lakhani
K H
KH
Paterson
S
S
Wood
J L
JL
Chanter
N
N
D000658:Amoxicillin / Q000627:therapeutic use*; D000818:Animals; D019818:Clavulanic Acid / Q000627:therapeutic use*; D002981:Clindamycin / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D011711:Pyoderma / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D013997:Time Factors
D004791:Enzyme Inhibitors; D019818:Clavulanic Acid; D002981:Clindamycin; D000658:Amoxicillin